Eli Lilly Retatrutide Shows Strong Phase 3 Diabetes Results!
INDIANAPOLIS, October 28, 2026 Eli Lilly and Company has announced positive topline results from its Phase 3 TRANSCEND-T2D-2 clinical...
GLP-1
Advertisement
Eccogene Receives $50M Milestone After Elecoglipron Phase 3 Start
BOSTON and SHANGHAI — September 28, 2026 Eccogene announced that it has received a $50 million milestone payment from...
Kither Biotech Doses First Patients in KIT2014 COPD Trial
TURIN, Italy — September 29, 2026 Kither Biotech Pty Ltd and Kither Biotech Srl announced that the first patients...
Cyprumed Oral Delivery Technology Enters Clinical Stage With MSD
INNSBRUCK, Austria — September 29, 2026 Cyprumed GmbH announced that MSD has initiated a Phase 1 clinical trial of...
Caspian Unveils KO-7246 Preclinical Diabetes Data at EASD
SAN DIEGO — September 29, 2026 Caspian Therapeutics and Kura Oncology announced new preclinical data for KO-7246, an investigational,...
Advertisements
Wave Initiates Phase 2a WVE-007 Combination Trial for Obesity
CAMBRIDGE, Mass. — September 23, 2026 Wave Life Sciences announced the initiation of a Phase 2a clinical trial evaluating...
Artelo Files Patent for ART27.13 in Obesity
SOLANA BEACH, Calif. — September 23, 2026 Artelo Biosciences announced that it has filed a new provisional patent application...
Viking Therapeutics Reports Positive VK2735 Weight Results
San Diego, California, U.S., September 22, 2026 Viking Therapeutics, Inc. has announced positive topline results from a maintenance study...
Zealand Pharma Initiates Phase 3 ZUPREME Program for Petrelintide
COPENHAGEN, Denmark — September 22, 2026 Zealand Pharma announced the initiation of the global registrational Phase 3a ZUPREME program...
Novo Nordisk Reports Positive Phase 3 CagriSema Resultsx
Bagsværd, Denmark, September 21, 2026 Novo Nordisk has announced topline results from two Phase 3 trials evaluating CagriSema, an...
Advertisement
